Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00096434
Other study ID # NCI-2012-01817
Secondary ID NCI-2012-01817CD
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2004

Study information

Verified date March 2024
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well sorafenib works in treating patients with metastatic breast cancer. Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.


Description:

OBJECTIVES: I. Determine the tumor response rate in patients with metastatic breast cancer previously treated with an anthracycline- and/or taxane-containing regimen receiving sorafenib. II. Assess the toxicity profile of this drug in these patients. III. Determine time to disease progression and survival time of patients treated with this drug. IV. Correlate pre-treatment levels of activated ERK1/2 with tumor response in patients treated with this drug. OUTLINE: This is a multicenter study. Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months until disease progression and then every 3 months for up to 5 years.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date
Est. primary completion date June 2006
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed breast cancer - Clinical evidence of metastatic disease - Measurable disease - HER2-positive or -negative disease - If HER2 gene amplified or strongly positive for HER2 by immunohistochemistry, patient must have had prior treatment containing trastuzumab (Herceptin®) unless contraindicated - Previously treated with anthracycline- and/or taxane-containing regimen in the neoadjuvant, adjuvant, or metastatic setting - Candidate for first- or second-line chemotherapy for metastatic disease - Core block or tumor slides of the primary or metastatic tumor available - No known brain metastases - Hormone receptor status: - Not specified - Male or female - Performance status - ECOG 0-1 - At least 3 months - WBC = 3,000/mm^3 - Absolute neutrophil count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Hemoglobin = 8.5 g/dL - No evidence of bleeding diathesis - Bilirubin = 1.5 times upper limit of normal (ULN) - AST = 3 times ULN - Alkaline phosphatase = 3 times ULN - PT normal - PTT normal - INR normal - Creatinine = 1.5 times ULN - Calcium normal - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia - No uncontrolled hypertension - No gastrointestinal tract disease that would preclude taking oral medication - No active peptic ulcer disease - Not pregnant or nursing - Fertile patients must use effective contraception - No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer - No history of allergic reaction attributed to compounds of similar chemical or biological composition to sorafenib or other study agents - No ongoing or active infection - No psychiatric illness or social situation that would preclude study participation - No other uncontrolled illness - See Disease Characteristics - More than 4 weeks since prior immunotherapy - No concurrent anticancer immunotherapy - No concurrent bevacizumab - See Disease Characteristics - More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered - No more than 1 prior chemotherapy regimen for metastatic disease - No concurrent anticancer chemotherapy - Prior hormonal therapy in the neoadjuvant, adjuvant, or metastatic setting is allowed - No concurrent anticancer hormonal therapy - No prior radiotherapy to = 25% of the bone marrow - More than 4 weeks since prior radiotherapy - More than 4 weeks since prior major surgery - No prior surgical procedure that would affect gastrointestinal absorption - No other concurrent drugs that target vascular endothelial growth factor (VEGF) or VEGF receptors - No concurrent antiretroviral therapy for HIV-positive patients - No other concurrent investigational agents - No other concurrent anticancer therapy - No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs, including any of the following: - Phenytoin - Carbamazepine - Phenobarbital - No concurrent rifampin - No concurrent Hypericum perforatum (St. John's wort) - No concurrent therapeutic anticoagulation - Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial devices is allowed

Study Design


Intervention

Drug:
sorafenib tosylate
Given orally
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States North Central Cancer Treatment Group Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of confirmed tumor responses, graded according to RECIST criteria A confirmed tumor response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. The tumor response rate is defined as the total number of eligible patients who achieved a complete or partial response according to the RECIST criteria divided by the total number of eligible patients enrolled on study. A 90% confidence interval for the true response rate will be constructed using the Duffy-Santner approach. Up to 5 years
Secondary Time to progression Estimated using the Kaplan-Meier method. Time from registration to disease progression, assessed up to 5 years
Secondary Survival time Estimated using the Kaplan-Meier method. Time from registration to death, assessed up to 5 years
Secondary Incidence of adverse events, graded according to the NCI-CTC version 3 The maximum grade for each type of toxicity will be recorded for each patient at each treatment evaluation. The frequency of each type of toxicity will be determined. Up to 5 years
See also
  Status Clinical Trial Phase
Completed NCT01987726 - Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Terminated NCT01918306 - GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer Phase 1/Phase 2
Terminated NCT01705340 - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Phase 1
Terminated NCT01222377 - Endoscopic Breast Surgery in Treating Patients With Breast Cancer N/A
Completed NCT00602043 - F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer Phase 2
Completed NCT00100750 - Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer Phase 1/Phase 2
Completed NCT00244881 - A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) Phase 2
Completed NCT00096109 - Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer Phase 2
Completed NCT00425672 - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment Phase 1/Phase 2
Completed NCT00057941 - Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer Phase 2
Terminated NCT02892734 - Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer Phase 2
Recruiting NCT03213041 - Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer Phase 2
Completed NCT02015559 - Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus Phase 2
Completed NCT02728596 - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) N/A
Completed NCT03364348 - 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Phase 1
Completed NCT02897375 - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Phase 1
Completed NCT01672684 - Phase I: At-Home Support for Rural Women Using Group Video Calling Phase 1
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1